Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex

Journal of Virology

Volumn 88, Issue 18, 2014, Pages 10459-10471

  Ruwona, Tinashe B ^a,b   Giang, Erick ^a   Nieusma, Travis ^a   Law, Mansun ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; DNA VACCINE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN PURIFICATION; SPLEEN CELL; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EPITOPE MAPPING; GENETICS; HEPACIVIRUS; HUMAN; IMMUNOLOGY; PROTEIN MOTIF; SERODIAGNOSIS; VIROLOGY;

AMINO ACID MOTIFS; ANIMALS; EPITOPE MAPPING; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS;

EID: 84906330457     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01584-14     Document Type: Article

References (74)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x.
2. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567. http://dx.doi.org/10.1016 /S1473-3099(05)70216-4.
3. Wasley A, Miller JT, Finelli L. 2007. Surveillance for acute viral hepatitis- United States, 2005. MMWR Surveill. Summ. 56(SS-03):1-24.
4. Leuchner L, Lindstrom H, Burstein GR, Mulhern KE, Rocchio EM, Johnson G, Schaffzin J, Smith P. 2008. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users-New York, November 2004-April 2007. (Reprinted fromMMWR 57:517-521, 2008).JAMA300:34-36. http://dx.doi.org/10.1001/jama.300 .1.34.
5. Kwo PY. 2012. Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Ther. Adv. Gastroenterol. 5:179-188. http://dx.doi.org/10.1177/1756283X11436317.
6. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 Investigators. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716. http://dx.doi.org/10.1016/S0140-6736(10)60934-8.
7. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. 2010. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362:1292- 1303. http://dx.doi.org/10.1056/NEJMoa0908014.
8. Gane E. 2012. Future perspectives: towards interferon-free regimens for HCV. Antivir. Ther. 17:1201-1210. http://dx.doi.org/10.3851/IMP2431.
9. Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53. http://dx.doi.org/10 .1007/978-1-59745-394-3_4.
10. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas WD, Jr, Szabo G, Finberg RW, Ambrosino DM, Babcock GJ. 2009. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83:12473-12482. http://dx.doi.org/10.1128/JVI.01138-09.
11. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
12. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 109:6205-6210. http://dx.doi.org/10.1073/pnas .1114927109.
13. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MA. 2007. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 104:16269-16274. http://dx.doi.org/10.1073/pnas.0705522104.
14. Keck ZY, Li TK, Xia JM, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SKH. 2008. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 82:6061-6066. http://dx.doi.org /10.1128/JVI.02475-07.
15. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. 2012. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8:e1002653. http://dx.doi.org/10.1371/journal.ppat.1002653.
16. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27. http: //dx.doi.org/10.1038/nm1698.
17. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973. http: //dx.doi.org/10.1128/JVI.01872-07.
18. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79:11095-11104. http://dx.doi.org/10.1128/JVI.79.17.11095-11104 .2005.
19. Schofield DJ, Bartosch B, Shimizu YK, Allander T, Alter HJ, Emerson SU, Cosset FL, Purcell RH. 2005. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42:1055-1062. http://dx.doi.org/10.1002/hep.20906.
20. Keck Z, Wang WY, Wang Y, Lau P, Carlsen THR, Prentoe J, Xia JM, Patel AH, Bukh J, Foung SKH. 2013. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J. Virol. 87:37. http://dx.doi.org/10.1128/JVI.01941-12.
21. Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitisCvirus that are critical for CD81 binding. J. Virol. 80:8695-8704. http://dx.doi.org/10.1128/JVI.00271-06.
22. Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS. 2011. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85:7005-7019. http://dx.doi.org/10.1128/JVI.00586-11.
23. Keck ZY, Sung VMH, Perkins S, Rowe J, Paul S, Liang TJ, Lai MMC, Foung SKH. 2004. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78:7257-7263. http://dx.doi.org/10.1128/JVI.78.13.7257-7263.2004.
24. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. 2012. Human monoclonal antibody HCV1 effectively prevents and treatsHCVinfection in chimpanzees. PLoS Pathog. 8:e1002895. http://dx.doi.org/10.1371/journal.ppat.1002895.
25. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. 2010. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28:6367-6373. http://dx.doi.org/10.1016/j.vaccine.2010 .06.084.
26. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M. 2013. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broadcross-genotype neutralizing antibodies in humans. PLoS One 8:e59776. http://dx.doi.org/10.1371/journal.pone.0059776.
27. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, Houghton M, Frey SE, Belshe RB. 2010. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 202:862-866. http://dx.doi.org/10.1086/655902.
28. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 91:1294- 1298. http://dx.doi.org/10.1073/pnas.91.4.1294.
29. Ray R, Khanna A, Lagging LM, Meyer K, Choo QL, Ralston R, Houghton M, Becherer PR. 1994. Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. J. Virol. 68: 4420-4426.
30. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M. 2007. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25: 7773-7784. http://dx.doi.org/10.1016/j.vaccine.2007.08.053.
31. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu ZY, Murthy K, Liang TJ. 2007. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl. Acad. Sci. U. S. A. 104:8427-8432. http://dx.doi.org/10.1073 /pnas.0702162104.
32. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chene I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3:94ra71. http://dx.doi.org/10.1126/scitranslmed.3002330.
33. Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cattaneo R. 2012. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J. Virol. 86:11558-11566. http://dx.doi.org/10 .1128/JVI.01776-12.
34. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M. 2007. Robust expansion of human hepatocytes in Fah//Rag2//Il2rg/ mice. Nat. Biotechnol. 25:903- 910. http://dx.doi.org/10.1038/nbt1326.
35. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. 2011. A genetically humanized mouse model for hepatitis C virus infection. Nature 474:208-211. http://dx.doi.org/10.1038/nature10168.
36. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:927-933. http://dx.doi.org/10.1038/90968.
37. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G. 2005. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41:847-856. http://dx.doi.org/10.1002/hep.20657.
38. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, Su L. 2011. A humanized mouse model to study hepatitisCvirus infection, immune response, and liver disease. Gastroenterology 140:1334-1344. http://dx.doi.org/10.1053/j.gastro.2011.01.001.
39. Law M, Cardoso RM, Wilson IA, Burton DR. 2007. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81:4272-4285. http://dx.doi.org/10.1128/JVI.02536-06.
40. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R. 2006. Enhancement of immune responses to anHBVDNAvaccine by electroporation. Vaccine 24:4490-4493. http://dx.doi.org/10.1016/j.vaccine.2005.08.014.
41. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68:6147-6160.
42. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944. http://dx.doi.org/10.1006 /viro.1995.1016.
43. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:6705-6711.
44. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642. http://dx.doi.org/10.1084/jem.20021756.
45. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. 2003. Hepatitis C virus glycoproteins mediate pHdependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U. S. A. 100:7271-7276. http://dx.doi.org/10.1073/pnas.0832180100.
46. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL. 2005. Characterization of hostrange and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265-274. http://dx.doi.org/10.1002/hep .20542.
47. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
48. Op De Beeck A, Montserret R, Duvet S, Cocquerel L, Cacan R, Barberot B, Le Maire M, Penin F, Dubuisson J. 2000. The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. J. Biol. Chem. 275:31428-31437. http://dx.doi .org/10.1074/jbc.M003003200.
49. Modis Y, Ogata S, Clements D, Harrison SC. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231. http://dx.doi.org/10.1128/JVI.79.2.1223 -1231.2005.
50. Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG. 2010. Structural changes of envelope proteins during alphavirus fusion. Nature 468:705-708. http: //dx.doi.org/10.1038/nature09546.
51. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, Thompson A, Bricogne G, Rey FA. 2010. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468:709-712. http://dx.doi.org/10.1038/nature09555.
52. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. 1999. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 17:1992-2002. http://dx.doi.org/10.1016/S0264 -410X(98)00448-4.
53. Tedeschi V, Akatsuka T, Shih JWK, Battegay M, Feinstone SM. 1997. A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology 25:459-462. http://dx.doi.org/10.1002/hep.510250234.
54. Kong L, Giang E, Nieusma T, Robbins JB, Deller MC, Stanfield RL, Wilson IA, Law M. 2012. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J. Virol. 86:13085-13088. http://dx.doi.org/10.1128/JVI.01939-12.
55. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. U. S. A. 109:9499- 9504. http://dx.doi.org/10.1073/pnas.1202924109.
56. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH. 2012. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J. Virol. 86:12923-12932. http://dx.doi.org /10.1128/JVI.02052-12.
57. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Selby M, Kuo G, Houghton M, Choo QL. 1993. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J. Virol. 67:6753-6761.
58. Brazzoli M, Helenius A, Foung SKH, Houghton M, Abrignani S, Merola M. 2005. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology 332:438-453. http://dx.doi.org/10.1016/j.virol.2004.11.034.
59. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH. 2011. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J. Infect. Dis. 204:1186- 1190. http://dx.doi.org/10.1093/infdis/jir511.
60. Meyer K, Banerjee A, Frey SE, Belshe RB, Ray R. 2011. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One 6:e23699. http://dx.doi.org/10.1371 /journal.pone.0023699.
61. Cocquerel L, Meunier JC, Op de Beeck A, Bonte D, Wychowski C,Dubuisson J. 2001. Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2. J. Gen. Virol. 82:1629-1635.
62. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. 1999. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 17:1992-2002.
63. Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspe G. 2001. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J. Virol. 75:12088-12097. http://dx .doi.org/10.1128/JVI.75.24.12088-12097.2001.
64. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344. http://dx.doi.org/10.1126/science.288.5464.339.
65. Lu L, Tatsunori N, Li CH, Waheed S, Gao FX, Robertson BH. 2008. HCV selection and HVR1 evolution in a chimpanzee chronically infected with HCV-1 over 12 years. Hepatol. Res. 38:704-716. http://dx.doi.org/10 .1111/j.1872-034X.2008.00320.x.
66. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68:1494-1500.
67. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SKH, Pecheur EI, Pietschmann T. 2010. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84:5751-5763. http://dx.doi.org /10.1128/JVI.02200-09.
68. Prentoe J, Jensen TB, Meuleman P, Serre SBN, Scheel TKH, Leroux-Roels G, Gottwein JM, Bukh J. 2011. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 85:2224-2234. http://dx.doi.org/10 .1128/JVI.01594-10.
69. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. 2011. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J. Exp. Med. 208:2599-2606. http: //dx.doi.org/10.1084/jem.20110740.
70. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MYW, Alter HJ, Feinstone SM. 2007. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. U. S. A. 104:8449-8454. http://dx.doi.org/10.1073/pnas.0703039104.
71. Krey T, Meola A, Keck ZY, Damier-Piolle L, Foung SK, Rey FA. 2013. Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog. 9:e1003364. http://dx .doi.org/10.1371/journal.ppat.1003364.
72. Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, Ball JK. 2012. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J. Virol. 86:2739-2749. http://dx .doi.org/10.1128/JVI.06492-11.
73. Drummer HE, Boo I, Maerz AL, Poumbourios P. 2006. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J. Virol. 80:7844-7853. http://dx.doi.org/10.1128/JVI.00029-06.
74. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601. http: //dx.doi.org/10.1002/hep.21088.